APOL1 G1 genotype modifies the association between HDLC and kidney function in African Americans

BMC Genomics

Charles N. Rotimi³  Barry I. Freedman⁴  Adebowale A. Adeyemo³  Orlando M. Gutiérrez¹  Ayo P. Doumatey³  Daniel Shriner³  Jasmin Divers²  Amy R. Bentley³ 

[1] Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA;Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA;Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA;Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, Winston-Salem, NC, USA

关键词: Glomerular filtration rate;    African ancestry;    High-density lipoprotein cholesterol;    Apolipoprotein L1;   

Others  :  1208958
DOI  :  10.1186/s12864-015-1645-7

 received in 2015-01-09, accepted in 2015-05-20,  发布年份 2015

【 摘 要 】

Background

Despite evidence of an association between variants at the apolipoprotein L1 gene (APOL1) locus and a spectrum of related kidney diseases, underlying biological mechanisms remain unknown. An earlier preliminary study published by our group showed that an APOL1 variant (rs73885319) modified the association between high-density lipoprotein cholesterol (HDLC) and estimated glomerular filtration rate (eGFR) in African Americans. To further understand this relationship, we evaluated the interaction in two additional large cohorts of African Americans for a total of 3,592 unrelated individuals from the Howard University Family Study (HUFS), the Natural History of APOL1-Associated Nephropathy Study (NHAAN), and the Atherosclerosis Risk in Communities Study (ARIC). The association between HDLC and eGFR was determined using linear mixed models, and the interaction between rs73885319 genotype and HDLC was evaluated using a multiplicative term.

Results

Among individuals homozygous for the risk genotype, a strong inverse HDLC-eGFR association was observed, with a positive association in others (p for the interaction of the rs73885319 × HDLC =0.0001). The interaction was similar in HUFS and NHAAN, and attenuated in ARIC. Given that ARIC participants were older, we investigated an age effect; age was a significant modifier of the observed interaction. When older individuals were excluded, the interaction in ARIC was similar to that in the other studies.

Conclusions

Based on these findings, it is clear that the relationship between HDLC and eGFR is strongly influenced by the APOL1 rs73885319 kidney risk genotype. Moreover, the degree to which this variant modifies the association may depend on the age of the individual. More detailed physiological studies are warranted to understand how rs73885319 may affect the relationship between HDLC and eGFR in individuals with and without disease and across the lifespan.

【 授权许可】

   
2015 Bentley et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI et al.. Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans. Science. 2010; 329(5993):841-845.
• [2]Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M et al.. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008; 40(10):1185-1192.
• [3]Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW et al.. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008; 40(10):1175-1184.
• [4]Thomson R, Genovese G, Canon C, Kovacsics D, Higgins MK, Carrington M, Winkler CA, Kopp J, Rotimi C, Adeyemo A, Doumatey A, Ayodo G, Alper SL, Pollak MR, Friedman DJ, Raper J: Evolution of the primate trypanolytic factor APOL1. Proceedings of the National Academy of Sciences. 2014;111(20):E2130–9.
• [5]Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P et al.. APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy. J Am Soc Nephrol. 2011; 22(11):2129-2137.
• [6]Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE et al.. End-stage renal disease in African Americans with Lupus Nephritis is associated with APOL1. Arthritis & Rheumatology. 2014; 66(2):390-396.
• [7]Parsa A, Kao WHL, Xie D, Astor BC, Li M, Hsu C-y et al.. APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease. New Engl J Med. 2013; 369(23):2183-2196.
• [8]Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study. Kidney Int. 2000; 58(1):293-301.
• [9]Odden MC, Tager IB, Gansevoort RT, Bakker SJL, Fried LF, Newman AB et al.. Hypertension and low HDL cholesterol were associated with reduced kidney function across the age spectrum: a collaborative study. Ann Epidemiol. 2013; 23(3):106-111.
• [10]Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C et al.. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003; 14(8):2084-2091.
• [11]Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T et al.. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2006; 71(2):159-166.
• [12]Krikken JA, Gansevoort RT, Dullaart RP. Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease. J Lipid Res. 2010; 51(7):1982-1990.
• [13]Hoebel S, de Ridder JH, Malan L. The association between anthropometric parameters, the metabolic syndrome and microalbuminuria in black Africans: the SABPA study. Cardiovasc J Afr. 2010; 21(3):148-152.
• [14]Bentley AR, Doumatey AP, Chen G, Huang H, Zhou J, Shriner D et al.. Variation in APOL1 Contributes to Ancestry-Level Differences in HDLc-Kidney Function Association. Int J Nephrol. 2012; 2012:748984.
• [15]Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. JASN. 2006; 17(4 Suppl 2):S145-147.
• [16]Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis. 1993; 22(1):72-82.
• [17]Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol. 2004; 24(1):46-53.
• [18]Dalrymple LS, Kaysen GA. The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol. 2008; 28(5):723-731.
• [19]Freedman BI, Langefeld CD, Turner J, Nunez M, High KP, Spainhour M et al.. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease. Kidney Int. 2012; 82(7):805-811.
• [20]Investigators TA. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989; 129(4):687-702.
• [21]Adeyemo A, Gerry N, Chen G, Herbert A, Doumatey A, Huang H et al.. A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet. 2009; 5(7): Article ID e1000564
• [22]Mailman MD, Feolo M, Jin Y, Kimura M, Tryka K, Bagoutdinov R et al.. The NCBI dbGaP database of genotypes and phenotypes. Nat Genet. 2007; 39(10):1181-1186.
• [23]Lustgarten JA, Wenk RE. Simple, Rapid, Kinetic Method for Serum Creatinine Measurement. Clin Chem. 1972; 18(11):1419-1422.
• [24]Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI et al.. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-612.
• [25]Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006; 38(8):904-909.
• [26]Shriner D. Investigating population stratification and admixture using eigenanalysis of dense genotypes. Heredity. 2011; 107(5):413-420.
• [27]Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated individuals. Genome Res. 2009; 19(9):1655-1664.
• [28]Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012; 40(D1):D930-D934.
• [29]Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-470.
• [30]Fornoni A, Merscher S, Kopp JB: Lipid biology of the podocyte[mdash]new perspectives offer new opportunities. Nat Rev Nephrol 2014, advance online publication.
• [31]Annema W, von Eckardstein A. High-Density Lipoproteins: Multifunctional but Vulnerable Protections from Atherosclerosis. Circulation Journal. 2013; 77(10):2432-2448.
• [32]Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM et al.. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. The Journal of Clinical Investigation. 1995; 96(6):2758-2767.
• [33]Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M et al.. Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease: Role of High-Density Lipoprotein–Proteome Remodeling. Circulation. 2013; 127(8):891-904.
• [34]Jensen MK, Rimm EB, Furtado JD, Sacks FM: Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease. J Am Heart Assoc. 2012;1:e000232.
• [35]Berrougui H, Isabelle M, Cloutier M, Grenier G, Khalil A. Age-related impairment of HDL-mediated cholesterol efflux. J Lipid Res. 2007; 48(2):328-336.
• [36]Jaouad L, de Guise C, Berrougui H, Cloutier M, Isabelle M, Fulop T et al.. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydyl groups. Atherosclerosis. 2006; 185(1):191-200.
• [37]Seres I, Paragh G, Deschene E, Fulop T, Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Experimental Gerontology. 2004; 39(1):59-66.
• [38]Ito K, Bick AG, Flannick J, Friedman DJ, Genovese G, Parfenov MG et al.. Increased Burden of Cardiovascular Disease in Carriers of APOL1 Genetic Variants. Circul Res. 2014; 114(5):845-850.
• [39]Langefeld CD, Divers J, Pajewski NM, Hawfield AT, Reboussin DM, Bild DE et al.. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int. 2015; 87(1):169-175.
• [40]Freedman BI, Langefeld CD, Lu L, Palmer ND, Smith SC, Bagwell BM et al.. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int. 2015; 87(1):176-181.